148 related articles for article (PubMed ID: 24577267)
1. Results of the College of American Pathology/American College of Medical Genetics and Genomics external proficiency testing from 2006 to 2013 for three conditions prevalent in the Ashkenazi Jewish population.
Feldman GL; Schrijver I; Lyon E; Palomaki GE;
Genet Med; 2014 Sep; 16(9):695-702. PubMed ID: 24577267
[TBL] [Abstract][Full Text] [Related]
2. Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.
Kalman L; Wilson JA; Buller A; Dixon J; Edelmann L; Geller L; Highsmith WE; Holtegaard L; Kornreich R; Rohlfs EM; Payeur TL; Sellers T; Toji L; Muralidharan K
J Mol Diagn; 2009 Nov; 11(6):530-6. PubMed ID: 19815695
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.
Tafe LJ; Datto MB; Palomaki GE; Lacbawan FL;
Genet Med; 2015 Jan; 17(1):58-62. PubMed ID: 24946157
[TBL] [Abstract][Full Text] [Related]
4. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
Colaianni A; Chandrasekharan S; Cook-Deegan R
Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
[TBL] [Abstract][Full Text] [Related]
5. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent.
ACOG Committee on Genetics
Obstet Gynecol; 2004 Aug; 104(2):425-8. PubMed ID: 15292027
[TBL] [Abstract][Full Text] [Related]
6. Carrier testing for autosomal-recessive disorders.
Vallance H; Ford J
Crit Rev Clin Lab Sci; 2003 Aug; 40(4):473-97. PubMed ID: 14582604
[TBL] [Abstract][Full Text] [Related]
7. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
Rozenberg R; Pereira Lda V
Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
[TBL] [Abstract][Full Text] [Related]
8. CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance.
Oglesbee D; Cowan TM; Pasquali M; Wood TC; Weck KE; Long T; Palomaki GE
Genet Med; 2018 Jan; 20(1):83-90. PubMed ID: 28661487
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys.
Lyon E; Schrijver I; Weck KE; Ferreira-Gonzalez A; Richards CS; Palomaki GE;
Genet Med; 2015 Mar; 17(3):219-25. PubMed ID: 25077647
[TBL] [Abstract][Full Text] [Related]
10. Results from an external proficiency testing program: 11 years of molecular genetics testing for myotonic dystrophy type 1.
Richards CS; Palomaki GE; Hegde M
Genet Med; 2016 Dec; 18(12):1290-1294. PubMed ID: 27253733
[TBL] [Abstract][Full Text] [Related]
11. Carrier screening panels for Ashkenazi Jews: is more better?
Leib JR; Gollust SE; Hull SC; Wilfond BS
Genet Med; 2005 Mar; 7(3):185-90. PubMed ID: 15775754
[TBL] [Abstract][Full Text] [Related]
12. ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent.
Obstet Gynecol; 2009 Oct; 114(4):950. PubMed ID: 19888064
[TBL] [Abstract][Full Text] [Related]
13. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
Kronn D; Jansen V; Ostrer H
Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
[TBL] [Abstract][Full Text] [Related]
14. Three-year experience of a CAP/ACMG methods-based external proficiency testing program for laboratories offering DNA sequencing for rare inherited disorders.
Richards CS; Palomaki GE; Lacbawan FL; Lyon E; Feldman GL;
Genet Med; 2014 Jan; 16(1):25-32. PubMed ID: 23703682
[TBL] [Abstract][Full Text] [Related]
15. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network.
Kaback M; Lim-Steele J; Dabholkar D; Brown D; Levy N; Zeiger K
JAMA; 1993 Nov; 270(19):2307-15. PubMed ID: 8230592
[TBL] [Abstract][Full Text] [Related]
16. Assessing the analytic validity of molecular testing for Huntington disease using data from an external proficiency testing survey.
Palomaki GE; Richards CS
Genet Med; 2012 Jan; 14(1):69-75. PubMed ID: 22237433
[TBL] [Abstract][Full Text] [Related]
17. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing.
Schneider A; Nakagawa S; Keep R; Dorsainville D; Charrow J; Aleck K; Hoffman J; Minkoff S; Finegold D; Sun W; Spencer A; Lebow J; Zhan J; Apfelroth S; Schreiber-Agus N; Gross S
Am J Med Genet A; 2009 Nov; 149A(11):2444-7. PubMed ID: 19876898
[TBL] [Abstract][Full Text] [Related]
18. The single cell as a tool for genetic testing: credibility, precision, implication.
Dotan K; Feldman B; Goldman B; Peri Y; Peleg L
J Assist Reprod Genet; 2010 Jun; 27(6):335-41. PubMed ID: 20198415
[TBL] [Abstract][Full Text] [Related]
19. Ethical Issues with Genetic Testing for Tay-Sachs.
Clayton T
J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
[TBL] [Abstract][Full Text] [Related]
20. Heterozygote screening for Tay-Sachs disease: past successes and future challenges.
Natowicz MR; Prence EM
Curr Opin Pediatr; 1996 Dec; 8(6):625-9. PubMed ID: 9018448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
